Chengyuan Fang

This paper engineers tumor-homing bacteria to display immune checkpoint-blocking nanobodies, showing enhanced tumor suppression in mouse models compared to traditional antibody therapies.

This paper shows that engineered probiotics converting lactate to pyruvate acutely alter microbiota and host metabolism but fail to improve chronic obesity, highlighting homeostatic limits of gut-targeted therapies.

This paper develops a CRISPRi system to suppress colibactin production in pks E. coli, reducing DNA damage and tumorigenesis in mice.